Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul 11;10(7):287.
doi: 10.3390/toxins10070287.

Gut Microbiota and Cardiovascular Uremic Toxicities

Affiliations
Review

Gut Microbiota and Cardiovascular Uremic Toxicities

Manuel T Velasquez et al. Toxins (Basel). .

Abstract

Cardiovascular disease (CVD) remains a major cause of high morbidity and mortality in patients with chronic kidney disease (CKD). Numerous CVD risk factors in CKD patients have been described, but these do not fully explain the high pervasiveness of CVD or increased mortality rates in CKD patients. In CKD the loss of urinary excretory function results in the retention of various substances referred to as "uremic retention solutes". Many of these molecules have been found to exert toxicity on virtually all organ systems of the human body, leading to the clinical syndrome of uremia. In recent years, an increasing body of evidence has been accumulated that suggests that uremic toxins may contribute to an increased cardiovascular disease (CVD) burden associated with CKD. This review examined the evidence from several clinical and experimental studies showing an association between uremic toxins and CVD. Special emphasis is addressed on emerging data linking gut microbiota with the production of uremic toxins and the development of CKD and CVD. The biological toxicity of some uremic toxins on the myocardium and the vasculature and their possible contribution to cardiovascular injury in uremia are also discussed. Finally, various therapeutic interventions that have been applied to effectively reduce uremic toxins in patients with CKD, including dietary modifications, use of prebiotics and/or probiotics, an oral intestinal sorbent that adsorbs uremic toxins and precursors, and innovative dialysis therapies targeting the protein-bound uremic toxins are also highlighted. Future studies are needed to determine whether these novel therapies to reduce or remove uremic toxins will reduce CVD and related cardiovascular events in the long-term in patients with chronic renal failure.

Keywords: adsorbents; indoles; intestinal microbiota; microbiome; microbiota; p-cresyl sulfate; prebiotics; probiotics; synbiotics; trimethylamine-oxide; uremic toxicities; uremic toxins.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Putative mechanisms linking uremic toxins to the development of cardiovascular disease.

References

    1. Sarnak M., Levey A. Cardiovascular disease and chronic renal disease: A new paradigm. Am. J. Kidney Dis. 2000;35:S117–S131. doi: 10.1016/S0272-6386(00)70239-3. - DOI - PubMed
    1. Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004;351:1296–1305. doi: 10.1056/NEJMoa041031. - DOI - PubMed
    1. Sarnak M.J., Levey A.S., Schoolwerth A.C., Coresh J., Culleton B., Hamm L.L., McCullough P.A., Kasiske B.L., Kelepouris E., Klag M.J., et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154–2169. doi: 10.1161/01.CIR.0000095676.90936.80. - DOI - PubMed
    1. Sarnak M.J., Levey A.S., Schoolwerth A.C., Gross M.L., Ritz E. Hypertrophy and fibrosis in the cardiomyopathy of uremia—Beyond coronary heart disease. Semin. Dial. 2008;21:308–318. - PubMed
    1. Weiner D.E., Tighiouart H., Elsayed E.F., Griffith J.L., Salem D.N., Levey A.S., Sarnak M.J. The relationship between non-traditional risk factors and outcomes in individuals with stage 3-4 CKD. Am. J. Kidney Dis. 2008;51:212–223. doi: 10.1053/j.ajkd.2007.10.035. - DOI - PMC - PubMed

Publication types

Substances